ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Covexin 8 – Carton
100 ml
250 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Covexin 8

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Contains:

Active Ingredient	**Potency value/ml**
C. perfringens type B & C (β) toxoid	≥ 14.4 U
C. perfringens type D (ε) toxoid	≥ 7.6 U
C. haemolyticum	≥ 15 U
C. chauvoei whole culture	meets Ph. Eur.
C. novyi type B toxoid	≥ 2.7 U
C. septicum toxoid	≥ 4.6 U
C. tetani toxoid	≥ 1.7 U

The vaccine contains potassium aluminium sulphate as an adjuvant, thiomersal as a preservative, and formaldehyde as a remnant of production.

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

100 ml
250ml

5. TARGET SPECIES

Clostridial vaccine for sheep and cattle

6. INDICATION(S)

For the active immunisation of sheep and cattle against diseases associated with infections caused by *C. perfringens* type B, *C. perfringens* type C, *C. perfringens* type D, *C. chauvoei*, *C. novyi* type B, *C. septicum* and *C. haemolyticum* and against tetanus caused by *C. tetani*.

For the passive immunisation of lambs and calves against infections caused by the above mentioned clostridial species (except C. *haemolyticum* in sheep).
The onset of immunity is two weeks after the primary course.

Duration of active immunity:
An anamnestic humoral immune response (immunological memory) to all components was demonstrated by serology 12 months following the primary course of vaccination.
Sheep: 12 months against *C. perfringens* type B, C and D, *C. novyi* type B, *C. tetani*
< 6 months against *C. septicum*, *C. haemolyticum*, *C. chauvoei*
Cattle: 12 months against *C. tetani* and *C. perfringens* type D
< 12 months against *C. perfringens* type B and C
< 6 months against *C. novyi* type B, *C. septicum*, *C. haemolyticum*, *C. chauvoei*.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Shake thoroughly before use.
For subcutaneous injection.

8. WITHDRAWAL PERIOD

Withdrawal period - zero days

9. SPECIAL WARNING(S), IF NECESSARY

Do not mix with any other medicinal product.
For further information on Uses, Dosage, Contra-indications and warnings, see package leaflet.

10. EXPIRY DATE

EXP:
Opened containers should be discarded within 8 hours of opening.

11. SPECIAL STORAGE CONDITIONS

Store and transport between +2°C and +8°C.
Protect from light.
Do not freeze.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Directions: see package leaflet.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only.

POM-VPS
To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey
KT22 7LP

16. MARKETING AUTHORISATION NUMBER

Vm 42058/4023

17. MANUFACTURER'S BATCH NUMBER

Lot No:

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Covexin 8 – vial label
100 ml
250 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Covexin 8
Suspension for injection
Clostridial vaccine for sheep and cattle

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Active Ingredient	**Potency value/ml**
C. perfringens type B & C (β) toxoid	≥ 14.4 U
C. perfringens type D (ε) toxoid	≥ 7.6 U
C. haemolyticum	≥ 15 U
C. chauvoei whole culture	meets Ph. Eur.
C. novyi type B toxoid	≥ 2.7 U
C. septicum toxoid	≥ 4.6 U
C. tetani toxoid	≥ 1.7 U

Adjuvant: Potassium aluminium sulphate
Preservative: Thiomersal

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

100 ml
250 ml

4. ROUTE(S) OF ADMINISTRATION

Shake thoroughly before use.
For subcutaneous injection.

5. WITHDRAWAL PERIOD

Withdrawal period – zero days

6. BATCH NUMBER

Lot No:

7. EXPIRY DATE

EXP:

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For further information: see package leaflet.
Store and transport between +2°C and +8°C.
Protect from light. Do not freeze.
Keep the container in the outer carton.
Do not mix with any other medicinal product.
Opened containers should be discarded within 8 hours of opening.
Keep out of reach and sight of children.
For animal treatment only.

MA holder:
Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey
KT22 7LP

Vm 42058/4023 POM-VPS

To be supplied only on veterinary prescription.

B. PACKAGE LEAFLET

PACKAGE LEAFLET FOR:
Covexin 8

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey
KT22 7LP

Manufacturer responsible for batch release:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Covexin 8
Suspension for injection

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Presentation
A suspension for injection containing:

Active Ingredient	**Potency value/ml**
C. perfringens type B & C (β) toxoid	≥ 14.4 U
C. perfringens type D (ε) toxoid	≥ 7.6 U
C. haemolyticum	≥ 15 U
C. chauvoei whole culture	meets Ph. Eur.
C. novyi type B toxoid	≥ 2.7 U
C. septicum toxoid	≥ 4.6 U
C. tetani toxoid	≥ 1.7 U

Also contains potassium aluminium sulphate (as adjuvant) and thiomersal (as preservative).

4. INDICATION(S)

For the active immunisation of sheep and cattle against diseases associated with infections caused by *C. perfringens* type B, *C. perfringens* type C, *C. perfringens* type D, *C. chauvoei*, *C. novyi* type B, *C. septicum* and *C. haemolyticum* and against tetanus caused by *C. tetani*.
For the passive immunisation of lambs and calves against infections caused by the above mentioned clostridial species (except *C. haemolyticum* in sheep).

The onset of immunity is two weeks after the primary course.

Duration of active immunity:
An anamnestic humoral immune response (immunological memory) to all components was demonstrated by serology 12 months following the primary course of vaccination.

Sheep: 12 months against *C. perfringens* type B, C and D, *C. novyi* type B, *C. tetani*
< 6 months against *C. septicum*, *C. haemolyticum*, *C. chauvoei*

Cattle: 12 months against *C. tetani* and *C. perfringens* type D
< 12 months against *C. perfringens* type B and C
< 6 months against *C. novyi* type B, *C. septicum*, *C. haemolyticum*, *C. chauvoei*

Duration of passive immunity as demonstrated by serology/persistent antibody titre only is

For lambs:
At least 2 weeks for *C. septicum* and *C. chauvoei*, at least 8 weeks for *C. perfringens* type B and *C. perfringens* type C and at least twelve weeks for *C. perfringens* type D, *C. novyi* type B and *C. tetani*. No passive immunity was observed for *C. haemolyticum*.

For calves:
At least 2 weeks for *C. haemolyticum*, at least 8 weeks for *C. septicum* and *C. chauvoei* and at least twelve weeks for *C. perfringens* type B, *C. perfringens* type C, *C. perfringens* type D, *C. novyi* type B, and *C. tetani*.

5. CONTRAINDICATIONS

None

6. ADVERSE REACTIONS

75 - 100% of vaccinated animals may experience reactions to vaccination. These reactions are usually localised swelling or induration at the injection site but may also include mild hyperthermia, abscess or other reaction in the underlying tissues at the injection site. Swelling at the injection site occurs in the majority of animals. This may reach up to 6 cm in sheep and 14 cm diameter in cattle. Most local reactions resolve within 3-6 weeks in sheep and in less than 10 weeks in cattle. In up to 17% of animals an abscess may develop.
Vaccination may give rise to reactions in the underlying tissues at the injection site. Skin discolouration (which returns to normal as the local reaction resolved) and localised pain for 1-2 days post first vaccination may occur at the injection site.
The local reactions do not affect the general health, demeanour, feeding or weight gain of the animals.
No side effects other than those described above are expected when the vaccine is used in sheep and cattle between 8 and 2 weeks prior to parturition. In the absence of specific data, no recommendation can be made for use of the vaccine during the first or second third of pregnancy.
Avoid stress in pregnant ewes and cows.

7. TARGET SPECIES

Closdridial vaccine for sheep and cattle

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Dose:
Primary vaccination:
Sheep and lambs over 8 weeks of age: 5 ml initial dose followed by a 2 ml dose 6 weeks later.

Lambs 2-8 weeks of age, from unvaccinated ewes or ewes of unknown vaccination status: 2 ml initial dose followed by a second 2 ml dose 4-6 weeks later.

Cattle of all ages: 5 ml initial dose followed by a second 5 ml dose 6 weeks later.

Revaccination:
A single dose (2 ml for sheep, 5 ml for cattle) should be administered at 12 month intervals.

Vaccination Programme:
Sheep: The vaccine course should be completed at least two weeks before maximum immunity is required. This may be either a period of risk or in pregnant ewes during lambing.

Use during pregnancy: In lambing flocks, to ensure maximum protection of the lambs until 12 weeks of age, previously vaccinated ewes are best injected 2 weeks before lambing is due to commence. However, provided lambing in the group will not extend beyond a 6 week period, previously vaccinated pregnant ewes may be injected at any time from 6 to 2 weeks before the group is due to commence lambing.

Lambs: Lambs born from fully vaccinated ewes should not be given their first dose of Covexin 8 until 8-12 weeks of age, since the presence of maternally derived antibodies may interfere with the response to *C. tetani* and *C. novyi* type B. Lambs born from unvaccinated ewes may be given their first dose of Covexin 8 from 2 weeks of age.

Cattle: The vaccine course should be completed at least two weeks before maximum immunity is required. This may be either a period of risk, or in pregnant cattle before calving.

Use during pregnancy: For passive protection of calves, previously vaccinated pregnant cattle should be vaccinated during the period 2-8 weeks before calving.

Calves: For an optimum immune response, calves from cows vaccinated during pregnancy should not be vaccinated until 8-12 weeks of age.

9. ADVICE ON CORRECT ADMINISTRATION

Administration:
By subcutaneous injection preferably in the loose skin on the side of the neck, observing aseptic precautions. The container should be shaken well before doses are withdrawn. Syringes and needles should be sterilized before use and the injection should be made through an area of clean, dry skin, taking aseptic precautions against contamination.

10. WITHDRAWAL PERIOD

Withdrawal period: Zero days

11. SPECIAL STORAGE PRECAUTIONS

Store and transport between +2°C and +8°C. Protect from light. Do not freeze. Opened containers should be discarded within 8 hours of opening. Do not mix with any other veterinary medicinal product. Avoid the introduction of contamination during use. Keep out of the reach and sight of children. For animal treatment only.

12. SPECIAL WARNING(S)

In the event of an anaphylactic reaction appropriate treatment such as adrenaline should be administered without delay.
No information is available on the safety and efficacy from the concurrent use of this vaccine with any other. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
In the case of accidental self-injection, encourage bleeding and wash the area immediately with water. If a local reaction develops, seek medical advice showing the package leaflet or the label to the physician.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused product or waste material should be disposed of in accordance with local requirements.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

August 2020

15. OTHER INFORMATION

Legal category
POM-VPS
To be supplied only on veterinary prescription.

Package quantities
100 ml and 250 ml plastic bottles. (Not all pack sizes may be marketed)

Further information
The effectiveness of the vaccine in providing passive immunity to young lambs and calves depends on these animals ingesting adequate amounts of colostrum on the first day of life.
Clinical trials have demonstrated that the presence of maternal antibodies, particularly against *C. tetani*, *C. novyi* type B, *C. perfringens* type A (calves only), *C. chauvoei* (lambs only) and *C. perfringens* type D may reduce the antibody response

to vaccination in young lambs and calves. Therefore, to ensure an optimal response in young animals with high levels of MDA, the primary vaccination should be delayed until the levels wane (which is after about 8-12 weeks of age).
In any animal population, there may be a number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon the correct storage and administration of the vaccine together with the animal's ability to respond. This can be influenced by such factors as genetic constitution, intercurrent infection, age, the presence of maternally derived antibodies, nutritional status, concurrent drug therapy and stress.

Marketing authorisation number Vm 42058/4023

Approved 19 August 2020